LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Transient neonatal Lambert-Eaton syndrome.

    Lecky, B R F

    Journal of neurology, neurosurgery, and psychiatry

    2006  Volume 77, Issue 9, Page(s) 1094

    MeSH term(s) Adult ; Female ; Humans ; Infant, Newborn ; Lambert-Eaton Myasthenic Syndrome/genetics ; Lambert-Eaton Myasthenic Syndrome/immunology ; Lambert-Eaton Myasthenic Syndrome/pathology ; Male ; Muscle Hypotonia/etiology ; Pregnancy ; Recurrence ; Remission, Spontaneous
    Language English
    Publishing date 2006-09
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 3087-9
    ISSN 1468-330X ; 0022-3050
    ISSN (online) 1468-330X
    ISSN 0022-3050
    DOI 10.1136/jnnp.2006.091504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Acute aphasia in MS revisited.

    Larner, A J / Lecky, B R F

    International MS journal

    2007  Volume 14, Issue 3, Page(s) 76–77

    MeSH term(s) Acute Disease ; Aphasia/epidemiology ; Aphasia/physiopathology ; Brain/pathology ; Female ; Humans ; Magnetic Resonance Imaging ; Middle Aged ; Multiple Sclerosis/epidemiology
    Language English
    Publishing date 2007-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2019791-3
    ISSN 1469-3410 ; 1352-8963
    ISSN (online) 1469-3410
    ISSN 1352-8963
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book ; Conference proceedings: Gammaglobulin treatment in neurology - fundamentals and clinical applications

    Lecky, B. R. F

    proceedings of a symposium held in Berlin, Germany, 25 - 27 November 1993

    (Journal of neurology, neurosurgery and psychiatry ; 57.1994, Suppl.)

    1994  

    Institution European Charcot Foundation for Multiple Sclerosis Research
    Event/congress Symposium on Gammaglobulin Treatment in Neurology: Fundamentals and Clinical Applications; (Berlin) (1993.11.25-27)
    Author's details suppl. ed.: B. R. F. Lecky
    Series title Journal of neurology, neurosurgery and psychiatry ; 57.1994, Suppl.
    Language English
    Size 75 S, graph. Darst
    Publisher BMJ
    Publishing place London
    Document type Book ; Conference proceedings
    Note Enth. überarb. Kongreßbeitr. ; Literaturangaben
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  4. Article: The District General Hospital as a Resource for the Provision of Neurological Services.

    Boggild, M D / Bowden, A N / Chadwick, D W / Doran, M / Enevoldson, T / Fletcher, N A / Hart, I / Humphrey, P / Lecky, B R F / Moore, A P / Smith, D / Steiger, M / Williams, I R / Young, C A

    Journal of the Royal College of Physicians of London

    2019  Volume 30, Issue 5, Page(s) 478–479

    Language English
    Publishing date 2019-01-22
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 3005-3
    ISSN 0035-8819
    ISSN 0035-8819
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Cerebral amyloid angiopathy with symptomatic or occult subarachnoid haemorrhage.

    Karabatsou, K / Lecky, B R F / Rainov, N G / Broome, J C / White, R P

    European neurology

    2007  Volume 57, Issue 2, Page(s) 103–105

    MeSH term(s) Aged ; Cerebral Amyloid Angiopathy/complications ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Subarachnoid Hemorrhage/etiology
    Language English
    Publishing date 2007
    Publishing country Switzerland
    Document type Case Reports ; Letter
    ZDB-ID 209426-5
    ISSN 1421-9913 ; 0014-3022
    ISSN (online) 1421-9913
    ISSN 0014-3022
    DOI 10.1159/000098060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

    Lilleker, J B / Rietveld, A / Pye, S R / Mariampillai, K / Benveniste, O / Peeters, M T J / Miller, J A L / Hanna, M G / Machado, P M / Parton, M J / Gheorghe, K R / Badrising, U A / Lundberg, I E / Sacconi, S / Herbert, M K / McHugh, N J / Lecky, B R F / Brierley, C / Hilton-Jones, D /
    Lamb, J A / Roberts, M E / Cooper, R G / Saris, C G J / Pruijn, G J M / Chinoy, H / van Engelen, B G M

    Annals of the rheumatic diseases

    2017  Volume 76, Issue 5, Page(s) 862–868

    Abstract: Objectives: Autoantibodies directed against cytosolic 5'-nucleotidase 1A have been identified in many patients with inclusion body myositis. This retrospective study investigated the association between anticytosolic 5'-nucleotidase 1A antibody status ... ...

    Abstract Objectives: Autoantibodies directed against cytosolic 5'-nucleotidase 1A have been identified in many patients with inclusion body myositis. This retrospective study investigated the association between anticytosolic 5'-nucleotidase 1A antibody status and clinical, serological and histopathological features to explore the utility of this antibody to identify inclusion body myositis subgroups and to predict prognosis.
    Materials and methods: Data from various European inclusion body myositis registries were pooled. Anticytosolic 5'-nucleotidase 1A status was determined by an established ELISA technique. Cases were stratified according to antibody status and comparisons made. Survival and mobility aid requirement analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression.
    Results: Data from 311 patients were available for analysis; 102 (33%) had anticytosolic 5'-nucleotidase 1A antibodies. Antibody-positive patients had a higher adjusted mortality risk (HR 1.89, 95% CI 1.11 to 3.21, p=0.019), lower frequency of proximal upper limb weakness at disease onset (8% vs 23%, adjusted OR 0.29, 95% CI 0.12 to 0.68, p=0.005) and an increased prevalence of excess of cytochrome oxidase deficient fibres on muscle biopsy analysis (87% vs 72%, adjusted OR 2.80, 95% CI 1.17 to 6.66, p=0.020), compared with antibody-negative patients.
    Interpretation: Differences were observed in clinical and histopathological features between anticytosolic 5'-nucleotidase 1A antibody positive and negative patients with inclusion body myositis, and antibody-positive patients had a higher adjusted mortality risk. Stratification of inclusion body myositis by anticytosolic 5'-nucleotidase 1A antibody status may be useful, potentially highlighting a distinct inclusion body myositis subtype with a more severe phenotype.
    MeSH term(s) 5'-Nucleotidase/immunology ; Age of Onset ; Aged ; Aged, 80 and over ; Autoantibodies/blood ; Biomarkers/blood ; Cytosol ; Electron Transport Complex IV/analysis ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Muscle Fibers, Skeletal/chemistry ; Muscle Fibers, Skeletal/pathology ; Muscle Weakness/etiology ; Myositis, Inclusion Body/blood ; Myositis, Inclusion Body/diagnosis ; Myositis, Inclusion Body/pathology ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Self-Help Devices/statistics & numerical data ; Survival Rate ; Time Factors
    Chemical Substances Autoantibodies ; Biomarkers ; Electron Transport Complex IV (EC 1.9.3.1) ; 5'-Nucleotidase (EC 3.1.3.5) ; NT5C1A protein, human (EC 3.1.3.5)
    Language English
    Publishing date 2017-01-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2016-210282
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Cerebral Amyloid Angiopathy with Symptomatic or Occult Subarachnoid Haemorrhage

    Karabatsou, K. / Lecky, B.R.F. / Rainov, N.G. / Broome, J.C. / White, R.P.

    European Neurology

    2006  Volume 57, Issue 2, Page(s) 103–105

    Institution Departments of Neurosurgery Neurology and Neuropathology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK
    Language English
    Publishing date 2006-12-15
    Publisher S. Karger AG
    Publishing place Basel, Switzerland
    Document type Article
    Note Letter to the Editor
    ZDB-ID 209426-5
    ISSN 1421-9913 ; 0014-3022
    ISSN (online) 1421-9913
    ISSN 0014-3022
    DOI 10.1159/000098060
    Database Karger publisher's database

    More links

    Kategorien

  8. Article ; Online: A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.

    Pritchard, J / Gray, I A / Idrissova, Z R / Lecky, B R F / Sutton, I J / Swan, A V / Willison, H J / Winer, J B / Hughes, R A C

    Neurology

    2003  Volume 61, Issue 9, Page(s) 1282–1284

    Abstract: The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously ... ...

    Abstract The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
    MeSH term(s) Cytokines/blood ; Disability Evaluation ; Dose-Response Relationship, Drug ; Fatigue/chemically induced ; Female ; Guillain-Barre Syndrome/drug therapy ; Guillain-Barre Syndrome/immunology ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Interferon beta-1a ; Interferon-beta/adverse effects ; Interferon-beta/therapeutic use ; Lymphopenia/chemically induced ; Male ; Middle Aged ; Pilot Projects ; Recombinant Proteins/adverse effects ; Recombinant Proteins/therapeutic use ; Treatment Outcome
    Chemical Substances Cytokines ; Immunoglobulins, Intravenous ; Recombinant Proteins ; Interferon-beta (77238-31-4) ; Interferon beta-1a (XRO4566Q4R)
    Language English
    Publishing date 2003-11-11
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/01.wnl.0000092019.53628.88
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top